减毒活病毒疫苗市场报告：2030 年趋势、预测与竞争分析

减毒活病毒疫苗的趋势与预测

到 2030 年，全球减毒活病毒疫苗市场预计将达到 98 亿美元，2024 年至 2030 年复合年增长率为 9.5%。该市场的主要驱动因素包括对更有效疫苗的需求不断增长、人们对疫苗接种益处的认识不断提高以及政府为加强疫苗接种计划而采取的支持措施。全球减毒活病毒疫苗市场前景广阔，医院、诊所、诊断中心和研究机构市场充满机会。

Lucintel 预测，由于病毒感染在有效预防病毒性行为感染的广泛应用，预计在预测期内性行为感染将出现高速成长。

在这个市场中，预计医院将在预测期内实现最高成长。

常问问题

Q.1减毒活病毒疫苗的市场规模有多大？

A1. 到 2030 年，全球减毒活病毒疫苗市场预计将达到 98 亿美元。

Q.2减毒活病毒疫苗市场的成长预测是多少？

A2. 2024年至2030年，全球减毒活病毒疫苗市场预计将以9.5%的复合年增长率成长。

Q.3 影响减毒活病毒疫苗市场成长的关键驱动因素有哪些？

A3. 该市场的主要驱动力是对更有效疫苗的需求不断增长、人们对疫苗接种益处的认识不断提高以及政府支持加强疫苗接种计划的倡议。

Q4.市场的主要细分市场是：

A4.减毒活病毒疫苗市场前景广阔，医院、诊所、诊断中心和研究机构市场充满机会。

Q5.市场的主要企业是：

A5. 主要减毒活病毒疫苗企业如下：

• GlaxoSmithKline
• Merck & Co
• Medimmune
• Sanofi
• Serum Institute India
• Emergent Biosolutions
• CSL

Q6.未来最大的细分市场是什么？

A6.Lucintel 预测，由于病毒在有效预防性行为感染的重要用途，预计在预测期内病毒将呈现高速成长。

Q7.未来五年预计哪些地区的市场成长最大？

A7. 由于其发达的医疗基础设施和政府疫苗宣传活动，预计北美在预测期内将出现最高的增长。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球减毒活病毒疫苗市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球减毒活病毒疫苗市场趋势（2018-2023）与预测（2024-2030）
• 按类型分類的全球减毒活病毒疫苗市场
  • 细菌
  • 病毒性的
• 按最终用途分類的全球减毒活病毒疫苗市场
  • 医院
  • 诊所
  • 诊断中心
  • 研究所
  • 其他的

第四章 2018-2030年区域市场趋势及预测分析

• 全球减毒活病毒疫苗市场区域分布
• 北美减毒活病毒疫苗市场
• 欧洲减毒活病毒疫苗市场
• 亚太地区减毒活病毒疫苗市场
• 其他地区减毒活病毒疫苗市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球减毒活病毒疫苗市场的成长机会（按类型）
  • 全球减毒活病毒疫苗最终用途市场成长机会
  • 全球减毒活病毒疫苗市场成长机会（按地区）
• 全球减毒活病毒疫苗市场新趋势
• 战略分析
  • 新产品开发
  • 全球减毒活病毒疫苗市场产能扩张
  • 全球减毒活病毒疫苗市场的合併、收购与合资企业
  • 认证和许可

第七章主要企业概况

• GlaxoSmithKline
• Merck & Co
  • MedImmune
• Sanofi
• Serum Institute India
• Emergent Biosolutions
• CSL

Live Attenuated Vaccine Trends and Forecast

The future of the global live attenuated vaccine market looks promising with opportunities in the hospital, clinic, diagnostics center, and research institute markets. The global live attenuated vaccine market is expected to reach an estimated $9.8 billion by 2030 with a CAGR of 9.5% from 2024 to 2030. The major drivers for this market are cumulating need for more effective vaccines, expanding awareness of the benefits of vaccination, and supportive government initiatives to promote vaccination programs.

Lucintel forecasts that viral is expected to witness higher growth over the forecast period due to its significant usage for the effective prevention of viral infections.

Within this market, hospital is expected to witness highest growth over the forecast period.

Emerging Trends in the Live Attenuated Vaccine Market

The live attenuated vaccine market is in flux, with a number of emerging trends pushing experimentation and market expansion. Included among these are technological advances being made with vaccines and the global fight against infectious diseases.

• Next-Generation Vaccine Development: An increasing emphasis is being placed on the production of newer live attenuated vaccines that are safer, more efficient and can target several pathogens simultaneously. Consequently, such vaccines are aimed at amplifying immune reactions while minimizing reactions thus making them applicable to various demographics.
• Alternative Delivery Methods: New ways of administering live attenuated vaccines like intranasal sprays and oral formulations have come up. Instead of traditional injections, these provide an easier means of administering the drug especially to pediatric as well as geriatric patients and they also offer better vaccine availability in countries lacking robust healthcare systems.
• Personalized Vaccination: The market has witnessed a significant shift towards personalized vaccines that are based on individual genetic traits. These vaccines aim to fine-tune immune system responses using genetic factors which could potentially increase efficacy while reducing adverse effects thus leading to more personalized vaccination strategies.
• Global Distribution and Accessibility: Ensuring that the global distribution of live attenuated vaccines is done equitably is a growing issue of concern. Activities are being undertaken to increase vaccine distribution networks notably in the low- and middle-income nations. The partnerships between governments, NGOs, and pharmaceutical companies are key to global vaccination objectives.
• Regulatory Innovation: Regulatory authorities are increasingly adopting more flexible and fast approval procedures for live attenuated vaccines. This move has been occasioned by the need to respond rapidly to emerging public health threats, which in turn paves way for new vaccines' rapid entry into market.

These trends reshape live attenuated vaccine marketplace stimulating innovation, enhancing accessibility, and enabling the adaptation of immunizations to better address global health requirements.

Recent Developments in the Live Attenuated Vaccine Market

This market has been undergoing significant progress due to advancements in research, production, and global health initiatives. These advances are essential for improving vaccine effectiveness, reachability, and supply.

• mRNA-Enhanced Live Attenuated Vaccines: Incorporating mRNA technology into live attenuated vaccines is a landmark development. It is used for enhancing the immune response especially in influenza and COVID-19 vaccines resulting in improved efficacy and wider protection.
• Inhalable Vaccines: The development of inhalable live attenuated vaccines is a major milestone. This way provides an alternative mode of administration to injections that makes it easier and more acceptable for vaccination especially among pediatrics and elderly people.
• Vaccine Production Expansion: A housing vaccine production facilities' expansion particularly at India and China represents one major step forward. These expansions are aimed at meeting the increasing global demand for live attenuated vaccines so as they are available in developed as well as developing countries.
• Global Vaccine Distribution Initiatives: New partnerships and initiatives focused on global vaccine distribution are emerging most especially in low income middle-income nations. Such efforts will ensure fairness when accessing live attenuated vaccines while bridging global health disparities.
• Fast-Tracking of Regulations: Regulatory authorities are putting in place fast-tracked procedures for attenuated live vaccines, particularly during pandemics. Such a development speeds up the production of new vaccines and as such helps in dealing with emerging health issues without delays.

These changes are at the forefront of the Live attenuated vaccine industry to make vaccines more efficient, reach many people and be available all over the world to solve worldwide health problems.

Strategic Growth Opportunities for Live Attenuated Vaccine Market

The live attenuated vaccine market is having a number of strategic growth areas in different applications, which are primarily driven by technology changes and global demand for effective vaccines.

• Pediatric Immunization Programs: There is an expanding pediatric immunization programs that have significantly increased potential. Young children-focused live attenuated vaccines expand coverage and integrate them with national schedules preventing a critical gap in early life protection.
• Elderly Vaccination: The targeting of older people with live attenuated vaccines comprises one of the key growth opportunities. Concerning severe infections, this group has a greater risk which has necessitated the development of specific vaccines to heighten immune responses among aged adults.
• Travel and Military Vaccination: There is an emerging market segment for live attenuated vaccines custom-made for travelers/ military personnel. For example these groups encounter unique pathogens hence targeted vaccination is inevitable for their well-being.
• Pandemic Preparedness: The priority of developing live attenuated vaccines for pandemic preparedness has been increasing lately. This category of vaccine is critically required as it aids in stockpiling and emergency use during health crisis thus partakers contribute to overall global health security efforts.
• Cancer Vaccines: The development of living attenuated vaccines for cancer treatment is an innovative growth opportunity. These vaccines are designed to prompt the immune system to recognize and eliminate cancer cells, offering a new way of treating cancer.

Innovation and expansion are being driven by these strategic growth opportunities in the live attenuated vaccine market. By targeting key applications, the market can meet crucial health requirements and support worldwide vaccination programs.

Live Attenuated Vaccine Market Driver and Challenges

Various drivers and challenges influence the live attenuated vaccine market among them being technological, economic as well as regulatory factors that shape the development and distribution of these vaccines.

The factors responsible for driving the live attenuated vaccine market include:

1. Technological Advancements: Innovations in vaccine technology such as mRNA and vector-based approaches drives the development of more effective and safer live attenuated vaccines. These advancements are broadening the market and increasing vaccine uptake.

2. Increasing Public Health Awareness: One major driver is rising awareness about the significance of immunization for prevention of communicable diseases. Public health campaigns disseminate information about the benefits associated with live attenuated vaccines thereby leading to increased vaccination rates.

3. Government Support: Strong government support including financing vaccine research and developing infrastructure has facilitated the growth of this market. In addition, governments have played a big role in ensuring regulatory approval as well as distributing vaccines.

4. Global Disease Burden: Demand for effective vaccines is driven by an increasing burden of infectious diseases globally. With their ability to confer strong immunity, live attenuated vaccines are considered indispensable for reducing disease incidence and mortality rate.

5. Pandemic Response: Pandemics require prompt and effective response, which is a significant push factor. In pandemic preparedness plans, live attenuated vaccines are given priority because they can be developed quickly and cover broad ranges.

Challenges in the live attenuated vaccine market are:

1. Regulatory Complexity: This challenge of vaccine developers is made harder by the intricate nature of regulatory environments in various parts of the world. The market entry could be delayed due to the need to comply with different regulations leading to high development costs.

2. Vaccine Hesitancy: Vaccine hesitancy still exists despite overwhelming evidence on their efficacy. Disinformation and doubts about the safety of vaccines may lead to less people getting vaccinated hence hampering public health efforts.

3. Production and Distribution Bottlenecks: Consistent supply of live attenuated vaccines remains a problem especially in low resource settings. There is an issue with vaccine availability and accessibility that arises from production capacity limitations as well as distribution challenges that emerge.

Innovation and expansion are powerful drivers that shape the live attenuated vaccine market but there are also some challenges that need attention for proper adoption and access across broad audience. Overcoming these challenges is essential for the market to fulfill its potential in improving global health outcomes.

List of Live Attenuated Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies live attenuated vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the live attenuated vaccine companies profiled in this report include-

• GlaxoSmithKline
• Merck & Co
• Medimmune
• Sanofi
• Serum Institute India
• Emergent Biosolutions
• CSL

Live Attenuated Vaccine by Segment

The study includes a forecast for the global live attenuated vaccine by type, end use, and region.

Live Attenuated Vaccine Market by Type [Analysis by Value from 2018 to 2030]:

• Bacterial
• Viral

Live Attenuated Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospital
• Clinic
• Diagnostic Center
• Research Institute
• Others

Live Attenuated Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Live Attenuated Vaccine Market

The live attenuated vaccine market is witnessing significant advancements due to increased R&D investments, technological innovations, and growing demand for effective immunization strategies. Meanwhile, countries such as the U.S., China, Germany, India and Japan are leading this progress worldwide in live attenuated vaccines for preventing infectious diseases.

• United States: In the United States, recent developments in influenza and COVID-19 have focused on improving live attenuated vaccines. mRNA technology is being utilized by many firms to strengthen vaccine efficiency. On the other hand, FDA has sanctioned new formulations which target boosting immune responses specifically among young children and old people. Also, there are joint efforts between biotechnology companies and government agencies to expedite vaccine availability.
• China's live attenuated vaccine market has rapidly expanded especially after the emergence of COVID-19 pandemic in China. The government has invested heavily into vaccine development and manufacturing with an aim of increasing both local and international distributions. Furthermore, Chinese firms are fronting new ways of administering vaccines such as inhalable vaccines which are globally recognized for their simplicity during administration.
• Germany: Emphasis on innovation in live attenuated vaccines in Germany, especially in cancer and infectious disease prevention. New vaccine candidates, based on live attenuated vectors targeting specific pathogens, are being developed by German biotech firms. The country is also a part of global initiatives to enhance delivery and accessibility of vaccines so that new vaccines are taken to those people who do not have them.
• India: India plays a vital role in the manufacture and distribution of live attenuated vaccines due to its large scale production capabilities. In addition, recent developments have seen government-backed measures to improve vaccine manufacturing infrastructure and reduce costs. Moreover, Indian companies are reaching out globally while providing vaccinations to different nations as well as participating in worldwide vaccination drives.
• Japan: Concentration is on the next generation of improved safety and more effective live attenuated vaccines in Japan. Japanese government's focus is targeted at researching on emerging diseases for finding their possible vaccine options as well as improving internal productivity capacities. Furthermore, Japan teams up with the rest of world for development of regional health challenges like influenza and dengue fever specific vaccines among others.

Features of the Global Live Attenuated Vaccine Market

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Live attenuated vaccine market size by type, end use, and region in terms of value ($B).

Regional Analysis: Live attenuated vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, end uses, and regions for the live attenuated vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the live attenuated vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the live attenuated vaccine market size?

Answer: The global live attenuated vaccine market is expected to reach an estimated $9.8 billion by 2030.

Q.2 What is the growth forecast for live attenuated vaccine market?

Answer: The global live attenuated vaccine market is expected to grow with a CAGR of 9.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the live attenuated vaccine market?

Answer: The major drivers for this market are cumulating need for more effective vaccines, expanding awareness of the benefits of vaccination, and supportive government initiatives to promote vaccination programs.

Q4. What are the major segments for live attenuated vaccine market?

Answer: The future of the live attenuated vaccine market looks promising with opportunities in the hospital, clinic, diagnostics center, and research institute markets.

Q5. Who are the key live attenuated vaccine market companies?

Answer: Some of the key live attenuated vaccine companies are as follows:

• GlaxoSmithKline
• Merck & Co
• Medimmune
• Sanofi
• Serum Institute India
• Emergent Biosolutions
• CSL

Q6. Which live attenuated vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that viral is expected to witness higher growth over the forecast period due to its significant usage for the effective prevention of viral infections.

Q7. In live attenuated vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the existence of well developed healthcare infrastructure and presence of supported government vaccination campaigns among individuals in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the live attenuated vaccine market by type (bacterial and viral), end use (hospital, clinic, diagnostics center, research institute, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Live Attenuated Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Live Attenuated Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Live Attenuated Vaccine Market by Type
  • 3.3.1: Bacterial
  • 3.3.2: Viral
• 3.4: Global Live Attenuated Vaccine Market by End Use
  • 3.4.1: Hospital
  • 3.4.2: Clinic
  • 3.4.3: Diagnostic Center
  • 3.4.4: Research Institute
  • 3.4.5: others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Live Attenuated Vaccine Market by Region
• 4.2: North American Live Attenuated Vaccine Market
  • 4.2.1: North American Live Attenuated Vaccine Market by Type: Bacterial and Viral 4.2.2: North American Live Attenuated Vaccine Market by End Use: Hospital, Clinic, Diagnostic Center, Research Institute, and Others
• 4.3: European Live Attenuated Vaccine Market
  • 4.3.1: European Live Attenuated Vaccine Market by Type: Bacterial and Viral
  • 4.3.2: European Live Attenuated Vaccine Market by End Use: Hospital, Clinic, Diagnostic Center, Research Institute, and Others
• 4.4: APAC Live Attenuated Vaccine Market
  • 4.4.1: APAC Live Attenuated Vaccine Market by Type: Bacterial and Viral
  • 4.4.2: APAC Live Attenuated Vaccine Market by End Use: Hospital, Clinic, Diagnostic Center, Research Institute, and Others
• 4.5: ROW Live Attenuated Vaccine Market
  • 4.5.1: ROW Live Attenuated Vaccine Market by Type: Bacterial and Viral
  • 4.5.2: ROW Live Attenuated Vaccine Market by End Use: Hospital, Clinic, Diagnostic Center, Research Institute, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Live Attenuated Vaccine Market by Type
  • 6.1.2: Growth Opportunities for the Global Live Attenuated Vaccine Market by End Use
  • 6.1.3: Growth Opportunities for the Global Live Attenuated Vaccine Market by Region
• 6.2: Emerging Trends in the Global Live Attenuated Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Live Attenuated Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Live Attenuated Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GlaxoSmithKline
• 7.2: Merck & Co
  • 7.1.1: MedImmune
• 7.4: Sanofi
• 7.5: Serum Institute India
• 7.6: Emergent Biosolutions
• 7.7: CSL